Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep + CAR-T therapy as explained by Mayo Clinic

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 19, 2022 7:54pm

175 Views

Post# 34972568

RE:RE:RE:RE:ONCY pelareorep + CAR-T therapy as explained by Mayo Clinic

ONCY has demonstrated that the combination of pelareorep with CAR-T therapy and immune checkpoint inhibitors provides an effective measure to improve both CAR-T and immune checkpoint inhibitor function.

Combining the 3 complementary therapies could prove to be an effective means to increase CAR-T persistence and durability, reverse an immunosuppressive tumor microenvironment (TME), as well as gaining the ability to overcome both antigen escape and resistance induced by T-cell immunotherapy and checkpoint blockade, respectively.

<< Previous

Bullboard Posts

Next >>

Three high-conviction small-cap stocks across the risk spectrum